Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Alnylam Pharma ( (ALNY) ) is now available.
On December 10, 2025, Alnylam Pharmaceuticals announced it had entered into privately negotiated repurchase agreements to buy back approximately $34.4 million of its 1.00% convertible senior notes due 2027 for about $51.9 million. This strategic financial move is expected to close shortly after an agreed measurement period, leaving approximately $362.8 million of the notes outstanding. The repurchase is part of Alnylam’s broader financial strategy, maintaining its capped call transactions and potentially impacting its financial profile and stakeholder interests.
The most recent analyst rating on (ALNY) stock is a Buy with a $508.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.
Spark’s Take on ALNY Stock
According to Spark, TipRanks’ AI Analyst, ALNY is a Neutral.
Alnylam Pharma’s overall score is driven by strong earnings call results and robust revenue growth, tempered by high leverage and valuation concerns. The technical indicators suggest moderate market sentiment, while the high P/E ratio indicates potential overvaluation.
To see Spark’s full report on ALNY stock, click here.
More about Alnylam Pharma
Alnylam Pharmaceuticals, Inc., headquartered in Cambridge, MA, is a leading company in RNA interference (RNAi) therapeutics, focusing on developing innovative medicines for rare and prevalent diseases. Their commercial products include AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, with partnerships for other products with Novartis and Sanofi. Alnylam is executing its ‘Alnylam P5x25’ strategy to deliver transformative medicines globally.
Average Trading Volume: 1,082,368
Technical Sentiment Signal: Buy
Current Market Cap: $54.85B
Learn more about ALNY stock on TipRanks’ Stock Analysis page.